Cosmax (A192820) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
20 Feb, 2026Executive summary
Q4 2024 saw robust growth in Korea and Southeast Asia, slow recovery in China, and negative growth in the US.
Net profit turned positive year-over-year, with significant improvement in operating profit margin.
Strong demand for indie brands and exports drove Korea's performance, while Southeast Asia benefited from local brand preference and export growth.
Financial highlights
Q4 2024 consolidated sales reached 558.0 KRW bn, up 27.8% year-over-year.
Operating profit rose 76.8% to 39.8 KRW bn; net profit turned positive at 12.9 KRW bn.
Gross profit increased 40.2% to 108.0 KRW bn; OPM hit a record 7.2% for Q4.
COGS ratio was 82.8%, SG&A cost ratio 8.2%, aided by a 2bn bad debt reversal.
Outlook and guidance
Continued strong demand expected in Korea and Southeast Asia.
China market remains challenging but shows signs of improvement, especially in Guangzhou.
US outlook cautious due to order delays and slow new client ramp-up.
Latest events from Cosmax
- Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.A192820
Q4 20258 Mar 2026 - Korea and Southeast Asia drove robust profit growth, offsetting China and US weakness.A192820
Q3 202420 Feb 2026 - Q2 2024 delivered double-digit sales and profit growth, driven by Korea and Southeast Asia.A192820
Q2 202420 Feb 2026 - Revenue and operating profit grew, but net profit dropped due to one-off and non-operating losses.A192820
Q1 202520 Feb 2026 - Revenue up 1.0% YoY, but net loss widened on one-off costs; BTI outperformed.A192820
Q3 202520 Feb 2026 - Record revenue and profit growth offset by net profit decline from non-operating expenses.A192820
Q2 202512 Aug 2025